AndreaBozzo/ceres-open-data-index huggingface dataset:
Patent AT-E401671-T1: [Translated] HALL EFFECT ELEMENT WITH INTEGRATED DEVIATION CONTROL AND METHOD FOR OPERATING SUCH AN ELEMENT FOR REDUCING THE ZERO POINT DEVIATION

A Hall-effect element includes an isolating layer and an active layer of a first electrical conductivity type disposed on the isolating layer, the active layer having a surface. A first set of contacts is disposed in contact with the surface along a first axis, and a second set of contacts is disposed in contact with the surface along a second axis transverse to the first axis. An insulating layer is disposed on the surface. A metal control field plate is disposed on the insulating layer and is coupleable to a voltage source to control the accumulation of charge carriers at the surface of the active layer to vary the resistance of the active layer. Also, a method is provided for reducing null offset in a Hall-effect element. The method includes the steps of providing an isolating layer, disposing an active layer of a first electrical conductivity type on the isolating layer, the active layer having a surface, disposing a first set of contacts on the surface along a first axis, disposing a second set of contacts on the surface along a second axis transverse to the first axis; and disposing an insulating layer on the surface. A voltage is applied across the insulating layer to control the accumulation of charge carriers at the surface to vary the resistance of the active layer.
2020 Mental Health Client-Level Data (MH-CLD) Annual Report

This report presents results from the Mental Health Client-Level Data (MH-CLD) and Mental Health Treatment Episode Data Set (MH-TEDS) for individuals receiving mental health services from state mental health systems in 2020, as well as selected trends in data collected from such individuals between 2015 and 2020. The report provides information on mental health diagnoses, mental health treatment settings, and demographic and substance use characteristics of individuals in mental health treatment in facilities that reported to individual state administrative data systems.
Pediatric Hospital Inpatient Sepsis Performance Measures by Facility: 2015 and 2016

Sepsis is defined as a clinical syndrome in which patients have an infection that is accompanied by an extreme systemic response. Sepsis of sufficient severity that the function of major organ systems in the body (such as heart, kidney, brain, and others) is impaired is referred to as “severe sepsis.” Patients with severe sepsis that have continued organ system impairment and/or low blood pressure that does not respond to treatment with adequate fluid replacement are considered to be in “septic shock.”  The combination of early detection of sepsis coupled with timely, appropriate interventions can significantly improve the chances of survival for patients with all types of sepsis.

The datasets contain hospital-level treatment measures for pediatric (age < 18) patients with a diagnosis of severe sepsis or septic shock seen at New York State Article 28 (acute care) facilities and reported to the New York State Department of Health in 2015 and 2016.

The treatment measures are presented by hospital.  Only hospital level measure data for which there were at least ten cases in the denominator is reported.  Statewide measures are calculated using all hospitals, regardless of the number of sepsis cases treated.
county-level ASD prevalence estimates

This table provides county-level prevalence for 2018 for seven US states using linked statewide health and education data. For full methods see:
Shaw KA, Williams S, Hughes MM, Warren Z, Bakian AV, Durkin MS, et al. Statewide county-level autism spectrum disorder prevalence estimates — seven U.S. states, 2018. Annals of Epidemiology. 2023 Jan 18; Available from: https://www.sciencedirect.com/science/article/pii/S1047279723000182
Compound 528687: Benzene, 1-ethyl-2-(1-methylpropyl)

Chemical compound data from PubChem database. IUPAC Name: 1-butan-2-yl-2-ethylbenzene. Molecular Formula: C12H18. Molecular Weight: 162.27. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
β1 integrins show specific association with CD98 protein in low density membranes

Background
          The CD98 (4F2, FRP-1) is a widely expressed cell surface protein heterodimer composed of a glycosylated heavy chain and a non-glycosylated light chain. Originally described as a T cell activation antigen, it was later shown to function in amino acid transport, cell fusion and homotypic cell aggregation. Several lines of evidence suggest its functional interaction with integrins but the biochemical basis for this interaction has been unclear.
        
        
          Results
          We demonstrate that CD98 constitutively and specifically associates with β1 integrins (α2β1,α3β1, α5β1 and α6β1), but minimally with α4β1. Integrin-CD98 association was established by reciprocal immunoprecipitation experiments, and confirmed by CD98-induced clustering of α3β1 but not α4β1 on the surface of rhabdomyosarcoma cells. Integrin-CD98 association is independent of the α subunit cytoplasmic tail, is maintained in α3β1 ligand-interaction deficient mutants, and is not inhibited by EDTA. Within the CD98 heavy chain, a C109S mutation (but not a C330S mutation) caused a loss of β1 integrin association. The same C109S mutation also caused a loss of CD98 light chain association. Importantly, CD98 associated selectively with β1 integrins present in low density "light membrane" fractions on a sucrose gradient. CD98 was not present in dense fractions that contained the majority of β1 integrins. Notably, the C109S mutant of CD98, that did not associate with β1 integrins, showed also a reduced localization into light membrane fractions.
        
        
          Conclusions
          We demonstrate that CD98 association with β1 integrins is specific, occurs in the context of low density membranes, and may require the CD98 light chain.
2022–2023 Nationwide Blood Donor Seroprevalence Survey Combined Infection- and Vaccination-Induced Seroprevalence Estimates

CDC is collaborating with Vitalant Research Institute, American Red Cross, and Westat Inc. to conduct a nationwide COVID-19 seroprevalence survey of blood donors. De-identified blood samples are tested for antibodies to SARS-CoV-2 to better understand the percentage of people in the United States who have antibodies against SARS-CoV-2 (the virus that causes COVID-19) and to track how this percentage changes over time. Both SARS-CoV-2 infection and COVID-19 vaccines currently used in the United States result in production of anti-spike (anti-S) antibodies but only infection results in production of anti-nucleocapsid (anti-N) antibodies.
Infection-induced seroprevalence estimates the proportion of the population with antibody evidence of previous SARS-CoV-2 infection and refers to the percent of the population with anti-nucleocapsid antibodies.
Combined infection-Induced and Vaccination-Induced seroprevalence estimates the proportion of the population with antibody evidence of previous SARS-CoV-2 infection, COVID-19 vaccination, or both, and refers to the percent of the population that has anti-spike antibodies, anti-nucleocapsid antibodies, or both.

This link connects to a webpage that displays the data from the Nationwide Blood Donor Seroprevalence Survey. It offers an interactive visualization available at https://covid.cdc.gov/covid-data-tracker/#nationwide-blood-donor-seroprevalence-2022
The effects of diesel exhaust inhalation on cardiovascular function

Air pollution serves as a major risk factor for the development of asthma, respiratory disease and heart disease. Diesel particulate and fumes are a major contributor to air pollution. Workers in a number of different occupations, including mining, oil and gas exploration and refining, and drivers of heavy equipment who are regularly exposed to diesel exhaust while on the job, and persons living in areas with high levels of air pollution, are at an increased risk for developing asthma, cardiovascular disease and certain cancers.

Understanding the physiological and cellular effects of diesel exhaust inhalation on Various organs in the body is critical for identifying exposure-induced biological and physiological markers of disease or dysfunction. The experiments in this manuscript, focus on the effects of diesel exhaust (DE) inhalation on peripheral and cardiovascular function. In the current studies, we hypothesized that the development of cardiovascular disease in workers regularly exposed to DE is the result of the inhalation of volatile gases and particulate within the vapor that affect the cardiovascular system by altering physiological and cellular processes that affect peripheral vascular responsiveness to agents that cause blood vessels to constrict and vessels that cause blood vessels to dilate, blood pressure, cardiac output and kidney function (kidney function as it may contribute to changes in blood pressure). We also predicted that these changes in physiology would be associated with changes in the expression of proteins and the production of genes that play a role in regulating oxidative stress, responses to decreases in oxygen, and markers of kidney function that are associated with blood pressure.
Patent AT-E400771-T1: [Translated] LAMP WITH DIODES

A lighting device (1; 101; 201; 301) for lighting objects is described, which comprises a printed circuit board (2) on which at least one LED light source (2) is mounted coupled to a primary optical assembly (3) for transmission and amplification of the light emitted by the light source, a containing body (5) enclosing the circuit board (2), and a secondary optical assembly (6) mounted on the containing body (5) at a suitable distance from the primary optical assembly (3) to generate at least one light beam leaving said lighting device.
Patent AT-E400301-T1: [Translated] ARTERIOVENOUS AND VENOUS TRANSPLANT TREATMENTS: METHODS AND COMPOSITIONS

A method and compounds are provided for inhibiting the synthesis of extracellular matrix proteins. Compounds of the invention comprise oligonucleotides specific for nuclear proto-oncogenes. Preferably, oligonucleotides of the invention are selected from the group consisting of c-myc and c-myb and are locally administered. The invention finds use in the treatment of a variety of disorders, including sclerotic disorders and restenosis, associated with the inappropriate synthesis of extracellular matrix proteins, particularly collagen.
Patent AT-E400948-T1: [Translated] SELECTIVE TRANSMISSION SPEED LIMITER FOR A FAST SPANNING TREE PROTOCOL

A network (e.g., RSTP-based network) and method are described herein that can selectively eliminate latencies in the exchange of to-be-transmitted control messages (e.g., BPDUs) between bridges during the re/convergence of the network. The method includes a step of classifying to-be-transmitted control messages as either low-priority control messages or high-priority control messages. The method also has a step of limiting the transmission rate of the low-priority control messages in accordance with a traditional IEEE 802.1 RSTP. And, the method also includes a step of immediately transmitting the high-priority control messages that contain information that contributes to the re/convergence of the network. <IMAGE>
District of Columbia (DC)

This report presents the District of Columbi\'s estimates for 25 measures of substance use and mental health based on the combined 2009 and 2010 National Surveys on Drug Use and Health (NSDUHs). Topics covered include past month substance use (e.g., illicit drugs, marijuana, cocaine, pain relievers, alcohol, tobacco), substance dependence, abuse, and treatment need, past year serious mental illness (SMI), any mental illness (AMI), suicidal thoughts, and major depressive episode (MDE). Resuts are provided for the District of Columbia for five age groups: 12 to 17, 18 to 25, 26 or older, 18 or older and all persons 12 or older.
NCHS Research and Development Survey (RANDS) Round 6 Restricted File

The Research and Development Survey (RANDS) is a series of cross-sectional surveys using probability-sampled commercial survey panels. The sixth round of RANDS (RANDS 6) was administered by NORC at the University of Chicago using the AmeriSpeak Panel from August 10, 2022 to August 29, 2022. RANDS 6 contained the embedded probe questions and experiments as in previous rounds of RANDS. It also explored different administrations of questions asked on the National Survey of Family Growth (NSFG) through split-sample experiments. RANDS 6 has a known survey sampling design and can be used to produce nationally and sub-nationally representative estimates.
Compound 526712: Pentaethylene glycol, nonyl ether

Chemical compound data from PubChem database. IUPAC Name: 2-[2-[2-[2-(2-nonoxyethoxy)ethoxy]ethoxy]ethoxy]ethanol. Molecular Formula: C19H40O6. Molecular Weight: 364.5. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Patent AT-E400253-T1: [Translated] METHOD FOR OBTAINING MICROPARTICLES WITH A H+, K+ -ATP-ASE INHIBITOR

A method for the preparation of homogenous microparticles containing a H<SUP>+</SUP>, K<SUP>+</SUP>-ATP-ase inhibitor using a fluid-bed granulation technique. The microparticles that have a desired size distribution are selected. At least 80% of the microparticle based on its dry weight content is the acid labile H<SUP>+</SUP>, K<SUP>+</SUP>-ATP-ase inhibitor.
Patent AT-E399829-T1: [Translated] PACKAGED GLASS TEMPERS

A packaged glass sealant product, is formed of a sealant composition having a processing temperature in the range of from greater than 70° C. up to 220° C. and a skin of thermoplastic polymeric material around said sealant composition. The skin constitutes no more than 10 wt % of the total weight of said product, and said polymeric material has a minimum film forming temperature of at least 50° C. and a softening point which is lower than the processing temperature for application of said sealant composition by a difference of more than 10° C. The product alleviates the necessity of disposing of non-recyclable, silicone coated packaging by environmentally unfriendly methods in particular land-fill.
Compound 528776: Cyclohentriacontasiloxane, dohexacontamethyl

Chemical compound data from PubChem database. IUPAC Name: 2,2,4,4,6,6,8,8,10,10,12,12,14,14,16,16,18,18,20,20,22,22,24,24,26,26,28,28,30,30,32,32,34,34,36,36,38,38,40,40,42,42,44,44,46,46,48,48,50,50,52,52,54,54,56,56,58,58,60,60,62,62-dohexacontamethyl-1,3,5,7,9,11,13,15,17,19,21,23,25,27,29,31,33,35,37,39,41,43,45,47,49,51,53,55,57,59,61-hentriacontaoxa-2,4,6,8,10,12,14,16,18,20,22,24,26,28,30,32,34,36,38,40,42,44,46,48,50,52,54,56,58,60,62-hentriacontasilacyclodohexacontane. Molecular Formula: C62H186O31Si31. Molecular Weight: 2298.8. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
PLACES: ZCTA Data (GIS Friendly Format), 2024 release

This dataset contains model-based ZIP Code Tabulation Area (ZCTA) level estimates in GIS-friendly format. PLACES covers the entire United States—50 states and the District of Columbia—at county, place, census tract, and ZIP Code Tabulation Area levels. It provides information uniformly on this large scale for local areas at four geographic levels. Estimates were provided by the Centers for Disease Control and Prevention (CDC), Division of Population Health, Epidemiology and Surveillance Branch. PLACES was funded by the Robert Wood Johnson Foundation in conjunction with the CDC Foundation. Data sources used to generate these model-based estimates are Behavioral Risk Factor Surveillance System (BRFSS) 2022 or 2021 data, Census Bureau 2020 population counts, and American Community Survey (ACS) 2018–2022 estimates. The 2024 release uses 2022 BRFSS data for 36 measures and 2021 BRFSS data for 4 measures (high blood pressure, high cholesterol, cholesterol screening, and taking medicine for high blood pressure control among those with high blood pressure) that the survey collects data on every other year. These data can be joined with the Census 2021 ZCTA boundary file in a GIS system to produce maps for 40 measures at the ZCTA level. An ArcGIS Online feature service is also available for users to make maps online or to add data to desktop GIS software.
https://cdcarcgis.maps.arcgis.com/home/item.html?id=3b7221d4e47740cab9235b839fa55cd7
Compound 529285: 3-Heptyne, 2,2,6,6-tetramethyl

Chemical compound data from PubChem database. IUPAC Name: 2,2,6,6-tetramethylhept-3-yne. Molecular Formula: C11H20. Molecular Weight: 152.28. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
NNDSS - TABLE 1LL. Vibriosis, Confirmed to Vibriosis, Probable

NNDSS - TABLE 1LL. Vibriosis, Confirmed to Vibriosis, Probable – 2022. In this Table, provisional cases* of notifiable diseases are displayed for United States, U.S. territories, and Non-U.S. residents.

Notes:

•	These are weekly cases of selected infectious national notifiable diseases, from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data reported by the 50 states, New York City, the District of Columbia, and the U.S. territories are collated and published weekly as numbered tables available at https://www.cdc.gov/nndss/data-statistics/index.html. Cases reported by state health departments to CDC for weekly publication are subject to ongoing revision of information and delayed reporting. Therefore, numbers listed in later weeks may reflect changes made to these counts as additional information becomes available. Case counts in the tables are presented as published each week. See also Guide to Interpreting Provisional and Finalized NNDSS Data at https://www.cdc.gov/nndss/docs/Readers-Guide-WONDER-Tables-20210421-508.pdf.
• Notices, errata, and other notes are available in the Notice To Data Users page at https://wonder.cdc.gov/nndss/NTR.html.
•	The list of national notifiable infectious diseases and conditions and their national surveillance case definitions are available at https://ndc.services.cdc.gov/. This list incorporates the Council of State and Territorial Epidemiologists (CSTE) position statements approved by CSTE for national surveillance.

Footnotes:

*Case counts for reporting years 2021 and 2022 are provisional and subject to change. Cases are assigned to the reporting jurisdiction submitting the case to NNDSS, if the case's country of usual residence is the U.S., a U.S. territory, unknown, or null (i.e. country not reported); otherwise, the case is assigned to the 'Non-U.S. Residents' category. Country of usual residence is currently not reported by all jurisdictions or for all conditions. For further information on interpretation of these data, see https://www.cdc.gov/nndss/docs/Readers-Guide-WONDER-Tables-20210421-508.pdf.
†Previous 52 week maximum and cumulative YTD are determined from periods of time when the condition was reportable in the jurisdiction (i.e., may be less than 52 weeks of data or incomplete YTD data).
U: Unavailable — The reporting jurisdiction was unable to send the data to CDC or CDC was unable to process the data.
-: No reported cases — The reporting jurisdiction did not submit any cases to CDC.
N: Not reportable — The disease or condition was not reportable by law, statute, or regulation in the reporting jurisdiction.
NN: Not nationally notifiable — This condition was not designated as being nationally notifiable.
NP: Nationally notifiable but not published.
NC: Not calculated — There is insufficient data available to support the calculation of this statistic.
Cum: Cumulative year-to-date counts.
Max: Maximum — Maximum case count during the previous 52 weeks.
Cefiderocol sulfate tosylate

Fetroja (cefiderocol sulfate tosylate) is an intravenous antibiotic powder used to treat serious bacterial infections. It belongs to the cephalosporin class and is administered by healthcare professionals. Manufactured by Shionogi Inc., it's available as a prescription drug in vials for reconstitution. This information was generated using AI and is provided for informational and research purposes only.
Population-Weighted Ultraviolet Irradiance, 2004-2015

This dataset provides data at the county level for the contiguous United States. It includes daily Ozone Monitoring Instrument (OMI) Population-Weighted Ultraviolet (UV) irradiance data from October 2004-2015 provided by the Environmental Remote Sensing group at the Rollins School of Public Health at Emory University. Please refer to the metadata attachment for more information.

These data are used by the CDC's National Environmental Public Health Tracking Network to generate sunlight and UV measures. Learn more about sunlight and UV on the Tracking Network's website: https://ephtracking.cdc.gov/showUVLanding.

By using these data, you signify your agreement to comply with the following requirements: 
1.	Use the data for statistical reporting and analysis only. 
2.	Do not attempt to learn the identity of any person included in the data and do not combine these data with other data for the purpose of matching records to identify individuals. 
3.	Do not disclose of or make use of the identity of any person or establishment discovered inadvertently and report the discovery to: trackingsupport@cdc.gov. 
4.	Do not imply or state, either in written or oral form, that interpretations based on the data are those of the original data sources and CDC unless the data user and data source are formally collaborating. 
5.	Acknowledge, in all reports or presentations based on these data, the original source of the data and CDC. 
6.	Suggested citation: Centers for Disease Control and Prevention. National Environmental Public Health Tracking Network. Web. Accessed: insert date. www.cdc.gov/ephtracking. 

Problems or Questions? 
Email trackingsupport@cdc.gov.
SHIP Emergency Department Visit Rate For Dental Care 2008-2017

This is historical data. The update frequency has been set to "Static Data" and is here for historic value. Updated on 8/14/2024

Emergency Department Visit Rate For Dental Care - This indicator shows the emergency department visit rate related to dental problems (per 100,000 population). The utilization of dental services in Emergency departments has steadily risen over the last decade. Dental Emergency department visits are growing as a percentage of all Emergency department visits throughout the United States. In 2014, there were 52,631 outpatient dental visits in Emergency department in Maryland.
Janus kinases and signal transducers and activators of transcription:		  their roles in cytokine signaling, development and immunoregulation

Cytokines play a critical role in the normal development and			 function of the immune system. On the other hand, many rheumatologic diseases			 are characterized by poorly controlled responses to or dysregulated production			 of these mediators. Over the past decade tremendous strides have been made in			 clarifying how cytokines transmit signals via pathways using the Janus kinase			 (Jak) protein tyrosine kinases and the Signal transducer and activator of			 transcription (Stat) proteins. More recently, research has focused on several			 distinct proteins responsible for inhibiting these pathways. It is hoped that			 further elucidation of cytokine signaling through these pathways will not only			 allow for a better comprehension of the etiopathogenesis of rheumatologic			 illnesses, but may also direct future treatment options.